Torbjörn Lundström

发表

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism

S. Schulman, P. Wessman, H. Eriksson, 2006, British journal of haematology.

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

C. Francis, J. Fiessinger, M. Huisman, 2005, JAMA.

Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis

C. Francis, J. Fiessinger, M. Huisman, 2005 .

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

D. Mozaffarian, P. Ridker, P. Barter, 2020, JAMA.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran

S. Schulman, H. Eriksson, K. Wåhlander, 2005, Thrombosis and Haemostasis.

Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

D. Mozaffarian, P. Ridker, P. Barter, 2018, Clinical cardiology.

Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia　- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study.

K. Niwa, K. Yokote, T. Yajima, 2020, Circulation journal : official journal of the Japanese Circulation Society.

Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia

K. Niwa, K. Yokote, T. Yajima, 2020 .

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega‐3‐Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single‐Blind, Randomized, Placebo‐Controlled Trial

T. Yajima, C. Nilsson, Torbjörn Lundström, 2018, Clinical pharmacology in drug development.

Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial

T. Yajima, C. Nilsson, Torbjörn Lundström, 2017, Journal of atherosclerosis and thrombosis.

Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation

S. Baumgartner, J. Miner, J. Oscarsson, 2018, Scientific Reports.

In Silico Comparison Between Metoprolol Succinate and Bisoprolol on 24-Hour Systolic Blood Pressures

S. Jansson, Torbjörn Lundström, Anders E. Malm, 2014, Drugs in R&D.

Ximelagatran for the secondary prevention of venous thromboembolism

S. Schulman, H. Eriksson, K. Wåhlander, 2005, Thrombosis and Haemostasis.

Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia

Paul D. Martin, J. Kastelein, B. Hamrén, 2015, European Journal of Clinical Pharmacology.

Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation

Jan Oscarsson, S. Baumgartner, Torbjörn Lundström, 2018, Scientific Reports.